Abstract

This application from a 10 hospital consortium in Southwest Washington State proposes to establish an NCI Community Clinical Research Program (CCOP). This program will increase the number of patients entered on NCI approved protocols, establish firm linkages between the community and two research bases (the Southwest Oncology Group and the Fred Hutchinson Cancer Research Center) and establish mechanisms to assist NCI in its test of the diffusion hypothesis. The diffusion hypothesis suggests that by entering patients on clinical therapeutic protocols the care of non-protocol patients will be improved. The Southwest Washington Community Clinical Oncology Program (SWWCCOP) was formed in 1981 to develop a strong community-wide cancer program. Over 148 primary care physicians cooperate in this effort. Building on this base, a small core group of oncologists with interest in clinical research, have developed a tightly-controlled, high quality control research plan, with the intent to enter 182 patients on trial.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10CA035281-03
Application #
3557709
Study Section
(SRC)
Project Start
1983-09-15
Project End
1987-05-31
Budget Start
1985-09-01
Budget End
1987-05-31
Support Year
3
Fiscal Year
1985
Total Cost
Indirect Cost

  Institution

Name
Multicare Health System
Department
Type
DUNS #
City
Tacoma
State
WA
Country
United States
Zip Code
98405

  Publications

Cheng, Heather H; Plets, Melissa; Li, Hongli et al. (2018) Circulating microRNAs and treatment response in the Phase II SWOG S0925 study for patients with new metastatic hormone-sensitive prostate cancer. Prostate 78:121-127
Samlowski, Wolfram E; Moon, James; Witter, Merle et al. (2017) High frequency of brain metastases after adjuvant therapy for high-risk melanoma. Cancer Med 6:2576-2585
Goldkorn, Amir; Ely, Benjamin; Tangen, Catherine M et al. (2015) Circulating tumor cell telomerase activity as a prognostic marker for overall survival in SWOG 0421: a phase III metastatic castration resistant prostate cancer trial. Int J Cancer 136:1856-62
Blumenthal, Deborah T; Rankin, Cathryn; Stelzer, Keith J et al. (2015) A Phase III study of radiation therapy (RT) and O?-benzylguanine + BCNU versus RT and BCNU alone and methylation status in newly diagnosed glioblastoma and gliosarcoma: Southwest Oncology Group (SWOG) study S0001. Int J Clin Oncol 20:650-8
Yu, Evan Y; Li, Hongli; Higano, Celestia S et al. (2015) SWOG S0925: A Randomized Phase II Study of Androgen Deprivation Combined With Cixutumumab Versus Androgen Deprivation Alone in Patients With New Metastatic Hormone-Sensitive Prostate Cancer. J Clin Oncol 33:1601-8
Budd, George T; Barlow, William E; Moore, Halle C F et al. (2015) SWOG S0221: a phase III trial comparing chemotherapy schedules in high-risk early-stage breast cancer. J Clin Oncol 33:58-64
Gralow, Julie R; Barlow, William E; Lew, Danika et al. (2014) A phase II study of docetaxel and vinorelbine plus filgrastim for HER-2 negative, stage IV breast cancer: SWOG S0102. Breast Cancer Res Treat 143:351-8
Yao, S; Sucheston, L E; Zhao, H et al. (2014) Germline genetic variants in ABCB1, ABCC1 and ALDH1A1, and risk of hematological and gastrointestinal toxicities in a SWOG Phase III trial S0221 for breast cancer. Pharmacogenomics J 14:241-7
Flaherty, Lawrence E; Othus, Megan; Atkins, Michael B et al. (2014) Southwest Oncology Group S0008: a phase III trial of high-dose interferon Alfa-2b versus cisplatin, vinblastine, and dacarbazine, plus interleukin-2 and interferon in patients with high-risk melanoma--an intergroup study of cancer and leukemia Group B, Ch J Clin Oncol 32:3771-8
Smerage, Jeffrey B; Barlow, William E; Hortobagyi, Gabriel N et al. (2014) Circulating tumor cells and response to chemotherapy in metastatic breast cancer: SWOG S0500. J Clin Oncol 32:3483-9

Showing the most recent 10 out of 109 publications